BOBAK YOUSSEFI: Open Payments
NPI 1528671955 · CAMBRIDGE, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,432 in 94 payments from 15 companies in 2025. Trend: 2023 $724 · 2024 $454 · 2025 $1,432
Food & beverage: $1,432
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $375 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $142 |
| Supernus Pharmaceuticals, Inc. | 7 | $115 |
| Janssen Pharmaceuticals, Inc | 4 | $98 |
| Axsome Therapeutics, Inc. | 4 | $91 |
| Alkermes, Inc. | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Neurocrine BioSciences, Inc. | 3 | $59 |
Products named: VRAYLAR, CAPLYTA, TRINTELLIX, Qelbree, INVEGA, Auvelity, REXULTI, HETLIOZ.
Industry payments across OH — which companies pay providers there.
